Xenon Pharmaceuticals (XENE) Change in Receivables (2013 - 2026)
Xenon Pharmaceuticals (XENE) reported Change in Receivables of -$205000.0 for Q1 2026, down 102.86% year-over-year from $7.2 million in Q1 2025, and down 136.67% quarter-over-quarter from $559000.0 in Q4 2025.
Xenon Pharmaceuticals (XENE) Change in Receivables (2013 - 2026) Analysis & Trends
Xenon Pharmaceuticals (XENE) has 14 years of Change in Receivables data on file, last reported at -$205000.0 in Q1 2026.
- Change in Receivables for Q1 2026 came in at -$205000.0, down 102.86% year-over-year; the trailing twelve-month figure through Mar 2026 was -$7.5 million (down 195.62% YoY), and the FY2025 annual result was -$104000.0, down 116.94% from the prior year.
- Change in Receivables declined to -$205000.0 in Q1 2026 per XENE's latest filing, from $559000.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $7.2 million in Q1 2025 and troughed at -$7.6 million in Q2 2025.
- A 5-year average of -$93058.8 and a median of -$38000.0 in 2024 frame the typical range for Change in Receivables.
- On a YoY basis, Change in Receivables climbed as much as 18989.47% in 2025 and fell as far as 34454.55% in 2025.
- A 5-year view of Change in Receivables shows it stood at -$1.5 million in 2022, then surged by 119.41% to $294000.0 in 2023, then jumped by 86.05% to $547000.0 in 2024, then climbed by 2.19% to $559000.0 in 2025, then plunged by 136.67% to -$205000.0 in 2026.
- Business Quant data shows XENE's Change in Receivables at -$205000.0 in Q1 2026, $559000.0 in Q4 2025, and -$283000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | Xenon Pharmaceuticals | 4.61 Bn | 4.61 Bn | - | -205,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -205,000.00 |
| Mar 31, 2026 | -205,000.00 |
| Dec 31, 2025 | 559,000.00 |
| Dec 31, 2025 | 559,000.00 |
| Sep 30, 2025 | -283,000.00 |
| Sep 30, 2025 | -283,000.00 |
| Jun 30, 2025 | -7.56 Mn |
| Jun 30, 2025 | -7.56 Mn |
| Mar 31, 2025 | 7.18 Mn |
| Mar 31, 2025 | 7.18 Mn |
| Dec 31, 2024 | 547,000.00 |
| Dec 31, 2024 | 547,000.00 |
| Sep 30, 2024 | 83,000.00 |
| Sep 30, 2024 | 83,000.00 |
| Jun 30, 2024 | 22,000.00 |
| Jun 30, 2024 | 22,000.00 |
| Mar 31, 2024 | -38,000.00 |
| Mar 31, 2024 | -38,000.00 |
| Dec 31, 2023 | 294,000.00 |
| Dec 31, 2023 | 294,000.00 |